Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | TYR | P14679 | 1/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131661 | 1.00 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19444747 | 0.90 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL71224 | 0.90 | CA12 (0.84) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5057418 | 0.90 | CA12 (0.84) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6661751 | 0.87 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6661748 | 0.87 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| Methyl P-Hydroxycinnamate SCHEMBL547438 | 0.82 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20653 | 0.82 | CA12 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL504081 | 0.82 | CA12 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2472987 | 0.82 | CA12 (0.72) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | claimed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | claimed |
| US-20170242174-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORPORATION (JP) | 2017-08-24 | — | — | US | claimed |
| EP-3208301-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | Tosoh Corporation (JP) | 2017-08-23 | — | — | EP | claimed |
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | disclosed |
| US-9862713-B2 | Substituted bicyclic heteroaryl compounds as RXR agonists | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20170242174-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORPORATION (JP) | 2017-08-24 | — | — | US | disclosed |
| EP-3208301-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | Tosoh Corporation (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20160333004-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS RXR AGONISTS | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-11-17 | — | — | US | disclosed |
| US-20120101039-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| WO-2010136036-A2 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20040225146-A1 | Tyrosine phosphatase scafold synthesis | KOLB HARTMUTH C (US) | 2004-11-11 | — | — | US | disclosed |
| EP-0821677-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033180-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225146-A1 | Tyrosine phosphatase scafold synthesis | PTPRC, PTPRCAP, PTPRS | CA12 3195/4885CA1 3310/4885CA2 1381/4885 |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CA12 3105/4885CA1 1902/4885CA2 2249/4885 |
| US-20120101039-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | CA12 756/4885CA1 220/4885CA2 13/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | CA12 2544/4885CA1 2640/4885CA2 1641/4885 |
| US-20160333004-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS RXR AGONISTS | RXRA, RXRB, RXRG | CA12 4745/4885CA1 4789/4885CA2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.